SOURCE: Collegium Pharmaceutical, Inc.

October 29, 2013 08:59 ET

"Challenges of Treating Patients With Chronic Pain With Dysphagia (CPD): Physician and Patient Perspectives," Published in Peer-Reviewed Medical Journal

11 Million Patients in the U.S. Suffer From Chronic Pain With Dysphagia; An Unmet Medical Need Exists for This Patient Population Due to Limitations Associated With Currently Available Treatments

CANTON, MA--(Marketwired - Oct 29, 2013) - Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of a research study in the peer-reviewed medical journal, Current Medical Research and Opinion. Two internationally recognized pain specialists, Dr. Joseph Pergolizzi, Jr. and Dr. Srinivas Nalamachu were co-authors on the publication.

Dr. Pergolizzi, the article's lead author, stated that "this study demonstrates that patients with moderate or severe chronic pain with dysphagia (CPD) are emerging as a patient population with an unmet medical need due to limitations associated with currently available extended-release (ER) opioid formulations, which can lead to inadequate analgesia and under-treatment of their chronic pain. These limitations may cause a decrease in treatment compliance in patients with CPD, resulting in lack of efficacy, adverse events, increased costs of therapy, and consequently, a greater financial burden on society. Furthermore, although all commercially-available ER opioid products carry warnings related to product tampering (e.g., potential for fatal overdose if chewed or crushed), the majority of patients in the study were not aware that chewing or crushing changes the release characteristics of the medication, which has the potential to lead to a fatal overdose."

The publication included results from two independently conducted physician and patient surveys which evaluated physician and patient's knowledge, attitudes and clinical management/analgesic usage patterns in the treatment of patients with CPD. Highlights from the study included:

  • 11 million people suffer from CPD across a variety of pain subtypes (e.g., chronic back pain, osteoarthritis, and cancer pain). The prevalence of CPD increases with age: 17% of pediatric (0-19 years of age), 24% of adult (20-64 years of age) and 59% of geriatric ( > 65 years of age) patients.
  • Approximately 30% of the 1,021 patients that were survey reported that they have trouble swallowing pills or do not like to swallow pills. In the absence of alternatives, approximately 16% of patients who cannot or do not like to swallow pills either crush or grind their pills in order to facilitate swallowing. The majority of patients in the study (65%) were not aware that crushing or grinding changes the release characteristics of the medication, which has the potential to lead to a fatal overdose
  • Physicians expressed a significant interest in the development of an oral, ER opioid that can be sprinkled onto food or taken directly by mouth and can be administered via a nasogastric or gastric tube without compromising the ER properties of the analgesic.

A copy of the publication is available at: Informa Healthcare.

About DETERx® Technology

The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents by sprinkling on soft food or via feeding tubes (nasogastric or gastrostomy), while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® is the first of a number of product candidates using the DETERx® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at

Contact Information